Transdermal delivery of bupropion and its active metabolite, hydroxybupropion: A prodrug strategy as an alternative approach

Journal of Pharmaceutical Sciences

Volumn 98, Issue 2, 2009, Pages 583-594

  Kiptoo, Paul K ^a   Paudel, Kalpana S ^a   Hammell, Dana C ^a   Pinninti, Raghotham Reddy ^a   Chen, Jianhong ^a   Crooks, Peter A ^a   Stinchcomb, Audra L ^a  

^a University of Kentucky   (United States)

Author keywords

Bupropion; Guinea pig skin; Human skin; Hydroxybupropion; LC MS; Pharmacokinetics; Prodrug; Transdermal drug delivery

Indexed keywords

AMFEBUTAMONE; DRUG METABOLITE; PRODRUG; RADAFAXINE; CARBAMIC ACID DERIVATIVE; DOPAMINE UPTAKE INHIBITOR; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STRUCTURE; FEMALE; GUINEA PIG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MASS SPECTROMETRY; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; SKIN ABSORPTION; ANIMAL; BIOLOGICAL MODEL; BLOOD; CHEMISTRY; DIFFUSION; DIFFUSION CHAMBER; DRUG STABILITY; HUMAN; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; PH; SKIN; SOLUBILITY;

ADMINISTRATION, CUTANEOUS; ANIMALS; BUPROPION; CARBAMATES; DIFFUSION; DIFFUSION CHAMBERS, CULTURE; DOPAMINE UPTAKE INHIBITORS; DRUG STABILITY; FEMALE; GUINEA PIGS; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MODELS, BIOLOGICAL; PRODRUGS; SKIN; SKIN ABSORPTION; SOLUBILITY;

EID: 59849117388     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21463     Document Type: Article

References (36)

1. Stewart JJ, Berkel HJ, Parish RC, Simar MR, Syed A, Bocchini JA Jr, Wilson JT, Manno JE. 2001. Single-dose pharmacokinetics of bupropion in adolescents: Effects of smoking status and gender. J Clin Pharmacol 41:770-778.
2. Fryer JD, Lukas RJ. 1999. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 288:88-92.
3. Miller DK, Sumithran SP, Dwoskin LP. 2002. Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. J Pharmacol Exp Ther 302:1113-1122.
4. Shepherd G, Velez LI, Keyes DC. 2004. Intentional bupropion overdoses. J Emerg Med 27:147-151.
5. Kelley JL, Musso DL, Boswell GE, Soroko FE, Cooper BR. 1996. (2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol: A novel antidepressant agent and selective inhibitor of norepinephrine uptake. J Med Chem 39:347-349.
6. Sweet RA, Pollock BG, Kirshner M, Wright B, Altieri LP, DeVane CL. 1995. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol 35:876-884.
7. Goldberg JP. 1990. Bupropion dose, seizures, women, and age. J Clin Psychiatry 51:388-389.
8. Midha KK, Junginger HE, Hirsh M. 2001. Patch and method for transdermal delivery of bupropion base. PAT US Patent No 6, 312, 716.
9. Midha KK, Rawson MJ, McKay G, Hubbard JW. 2005. Exposure measures applied to the bioequivalence of two sustained release formulations of bupropion. Int J Clin Pharmacol Ther 43:244-254.
10. Gidwani SK, Singnurkar P, Tewari PK. 2002. Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride. US Patent No 6, 462, 237.
11. Rotzinger S, Bourin M, Akimoto Y, Coutts RT, Baker GB. 1999. Metabolism of some "second"-and "fourth"-generation antidepressants: Iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine. Cell Mol Neurobiol 19:427-442.
12. Lai AA, Schroeder DH. 1983. Clinical pharmacokinetics of bupropion: A review. J Clin Psychiatry 44:82-84.
13. Bondarev ML, Bondareva TS, Young R, Glennon RA. 2003. Behavioral and biochemical investigations of bupropion metabolites. Eur J Pharmacol 474:85-93.
14. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, Lindley CM. 2000. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222-1230.
15. Golden RN, De Vane CL, Laizure SC, Rudorfer MV, Sherer MA, Potter WZ. 1988. Bupropion in depression. II. The role of metabolites in clinical outcome. Arch Gen Psychiatry 45:145-149.
16. Martin P, Massol J, Colin JN, Lacomblez L, Puech AJ. 1990. Antidepressant profile of bupropion and three metabolites in mice. Pharmacopsychiatry 23:187-194.
17. DeVane CL, Laizure SC, Cameron DF. 1986. The effect of experimentally-induced renal failure on accumulation of bupropion and its major basic metabolites in plasma and brain of guinea pigs. Psychopharmacology (Berl) 89:404-408.
18. Suckow RF, Zhang MF, Cooper TB. 1997. Enantiomeric determination of the phenylmorpholinol metabolite of bupropion in human plasma using coupled achiral-chiral liquid chromatography. Biomed Chromatogr 11:174-179.
19. Cooper TB, Suckow RF, Glassman A. 1984. Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual-wavelength ultraviolet detection. J Pharm Sci 73:1104-1107.
20. Vigroux A, Bergon M, Zedde C. 1995. Cyclization-activated prodrugs: N-(substituted 2-hydroxyphenyl and 2-hydroxypropyl)carbamates based on ring-opened derivatives of active benzoxazolones and oxazolidinones as mutual prodrugs of acetaminophen. J Med Chem 38:3983-3994.
21. Vlieghe P, Clerc T, Pannecouque C, Witvrouw M, De Clercq E, Salles JP, Kraus JL. 2001. New 3′-azido-3′-deoxythymidin-5′-yl O-(4-hydroxyalkyl or -alkenyl or -alkylepoxide) carbonate prodrugs: Synthesis and anti-HIV evaluation. J Med Chem 44:3014-3021.
22. Hamad MO, Kiptoo PK, Stinchcomb AL, Crooks PA. 2006. Synthesis and hydrolytic behavior of two novel tripartate codrugs of naltrexone and 6beta-naltrexol with hydroxybupropion as potential alcohol abuse and smoking cessation agents. Bioorg Med Chem 14:7051-7061.
23. Kiptoo PK, Hamad MO, Crooks PA, Stinchcomb AL. 2006. Enhancement of transdermal delivery of 6-beta-naltrexol via a codrug linked to hydroxybupropion. J Control Release 113:137-145.
24. Collier SW, Sheikh NM, Sakr A, Lichtin JL, Stewart RF, Bronaugh RL. 1989. Maintenance of skin viability during in vitro percutaneous absorption/ metabolism studies. Toxicol Appl Pharmacol 99:522-533.
25. Kalia YN, Alberti I, Sekkat N, Curdy C, Naik A, Guy RH. 2000. Normalization of stratum corneum barrier function and transepidermal water loss in vivo. Pharm Res 17:1148-1150.
26. Pillai O, Hamad MO, Crooks PA, Stinchcomb AL. 2004. Physicochemical evaluation, in vitro human skin diffusion, and concurrent biotransformation of 3-O-alkyl carbonate prodrugs of naltrexone. Pharm Res 21:1146-1152.
27. Hildebrand JH, Scott RL. 1950. The solubility of nonelectrolytes. Reinhold Pub: New York. Chap 12.
28. Potts RO, Guy RH. 1992. Predicting skin permeability. Pharm Res 9:663-669.
29. Roberts WJ, Sloan KB. 1999. Correlation of aqueous and lipid solubilities with flux for prodrugs of 5-fluorouracil, theophylline, and 6-mercaptopurine: A Potts-Guy approach. J Pharm Sci 88:515-522.
30. Roberts MS, Pugh WJ, Hadgraft J. 1996. Epidermal permeability: Penetrant structure relationships. 2. The effect of h-bonding groups in penetrants on their diffusion through the stratum corneum. Int J Pharm 132:23-32.
31. Pugh WJ, Degim IT, Hadgraft J. 2000. Epidermal permeability-penetrant structure relationships: 4, QSAR of permeant diffusion across human stratum corneum in terms of molecular weight, H- bonding and electronic charge. Int J Pharm 197:203-211.
32. Zhang D, Yuan B, Qiao M, Li F. 2003. HPLC determination and pharmacokinetics of sustained-release bupropion tablets in dogs. J Pharm Biomed Anal 33:287-293.
33. Loboz KK, Gross AS, Ray J, McLachlan AJ. 2005. HPLC assay for bupropion and its major metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 823:115-121.
34. Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Murdter TE, Roots I, Brockmoller J. 2003. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13:619-626.
35. Jennison TA, Brown P, Crossett J, Urry FM. 1995. A high-performance liquid chromatographic method for quantitating bupropion in human plasma or serum. J Anal Toxicol 19:69-72.
36. Worrall SP, Almond MK, Dhillon S. 2004. Pharmacokinetics of bupropion and its metabolites in haemodialysis patients who smoke. A. single dose study. Nephron Clin Pract 97:c83-c89.